Seroconversion rates following COVID-19 vaccination among patients with cancer.
Seroconversion rates following COVID-19 vaccination among patients with cancer.
复制标题
癌症患者疫苗接种后的血清转化率。
DOI：
10.1016/j.ccell.2021.06.002
复制
发表时间：
2021-08-09
期刊：
影响因子：
50.3
通讯作者：
Halmos B
中科院分区：
文献类型：
--
作者：
Thakkar A;Gonzalez-Lugo JD;Goradia N;Gali R;Shapiro LC;Pradhan K;Rahman S;Kim SY;Ko B;Sica RA;Kornblum N;Bachier-Rodriguez L;McCort M;Goel S;Perez-Soler R;Packer S;Sparano J;Gartrell B;Makower D;Goldstein YD;Wolgast L;Verma A;Halmos B
由于新冠病毒对癌症患者产生不良影响，预防性策略至关重要。我们使用一种经过验证的针对新冠病毒刺突蛋白的抗体检测方法，测定了纽约市200名癌症患者在接种美国食品药品监督管理局批准的一种新冠疫苗全剂量后的高血清转化率（94%）。与实体瘤患者（98%）相比，血液系统恶性肿瘤患者的血清转化率明显较低（85%），尤其是接受高度免疫抑制治疗（如抗CD20治疗（70%）和干细胞移植（73%））的患者。接受免疫检查点抑制剂治疗（97%）或激素治疗（100%）的患者在接种疫苗后显示出高血清转化率。既往感染过新冠病毒的患者在接种疫苗后显示出更高的抗刺突IgG滴度。接种腺病毒疫苗后的IgG滴度比接种基于信使核糖核酸的疫苗后相对较低。这些数据表明，新冠疫苗在肿瘤患者中通常具有较高的免疫原性，并确定了需要新的疫苗接种或被动免疫策略的免疫抑制人群。
通过评估针对新冠病毒刺突蛋白的IgG水平，塔卡尔等人在不同的癌症患者群体中展示了高血清转化率，同时确定了血液系统恶性肿瘤患者以及接受免疫抑制治疗的患者免疫原性较低。
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies. Evaluating the IgG levels against SARS-CoV-2 spike protein, Thakkar et al. demonstrate high rates of seroconversion in a diverse cohort of patients with cancer, while identifying lower immunogenicity in patients with hematologic malignancies and in patients having received immunosuppressive therapies.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s2352-3026(21)00110-1
发表时间：
2021-06
期刊：
The Lancet. Haematology
影响因子：
--
作者：
Bird S;Panopoulou A;Shea RL;Tsui M;Saso R;Sud A;West S;Smith K;Barwood J;Kaczmarek E;Panlaqui C;Kaiser M;Stern S;Pawlyn C;Boyd K
通讯作者：
Boyd K
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1016/j.annonc.2020.10.473
发表时间：
2021-01
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Marra A;Generali D;Zagami P;Cervoni V;Gandini S;Venturini S;Morganti S;Passerini R;Orecchia R;Curigliano G
通讯作者：
Curigliano G
影响因子：
28.2
作者：
Ribas A;Sengupta R;Locke T;Zaidi SK;Campbell KM;Carethers JM;Jaffee EM;Wherry EJ;Soria JC;D'Souza G;AACR COVID-19 and Cancer Task Force
通讯作者：
AACR COVID-19 and Cancer Task Force